Suplatast tosilate inhibits thymus- and activation-regulated chemokine production by antigen-specific human Th2 cells
Article first published online: 11 DEC 2002
Clinical & Experimental Allergy
Volume 32, Issue 12, pages 1782–1786, December 2002
How to Cite
Oda, N., Minoguchi, K., Tanaka, A., Yokoe, T., Minoguchi, H., Matsuo, H., Nakashima, M., Tasaki, T. and Adachi, M. (2002), Suplatast tosilate inhibits thymus- and activation-regulated chemokine production by antigen-specific human Th2 cells. Clinical & Experimental Allergy, 32: 1782–1786. doi: 10.1046/j.1365-2222.2002.01547.x
- Issue published online: 11 DEC 2002
- Article first published online: 11 DEC 2002
- Submitted 9 April 2002; revised 24 June 2002; accepted 10 September 2002
- suplatast tosilate;
- T cell;
- thymus- and activation-regulated chemokine;
Background Suplatast tosilate is an anti-allergic agent that suppresses cytokine production by human Th2 cells.
Objective We investigated the effects of suplatast tosilate on the production of thymus- and activation-regulated chemokine (TARC) by T cells from allergic patients with asthma.
Methods Purified protein derivative (PPD)-specific Th1 cell lines and Dermatophagoides farinae (Der f)-specific Th2 cell lines were established from nine patients with house dust mite-allergic asthma. The effects of suplatast tosilate on mRNA expression of TARC and protein production of TARC from antigen-specific Th1 or Th2 cell lines were investigated after stimulation with relevant antigens or phytohemagglutinin (PHA). In addition, the effects of IL-4, IL-10, and IFN-γ on TARC production by Der f-specific Th2 cell lines in the presence or absence of suplatast tosilate were studied.
Results Although PPD-specific Th1 cell lines did not produce TARC after stimulation with PPD antigen or PHA, stimulation of Der f-specific Th2 cell lines with Der f antigen or PHA increased production of TARC. Suplatast tosilate significantly and dose-dependently inhibited production of TARC by Der f-specific Th2 cell lines stimulated with either Der f antigen (76.5% inhibition at 100 µg/mL, P < 0.01) or PHA (81.9% inhibition at 100 µg/mL, P < 0.01). TARC production by Der f-specific Th2 cell lines was significantly increased only by activation with IL-4 but not with IL-10 or IFN-γ; this increase in TARC production was significantly inhibited by suplatast tosilate (97.5% inhibition at 100 µg/mL, P < 0.01).
Conclusion Suplatast tosilate inhibits TARC production by human Th2 cells. Therefore, this agent inhibits both Th2 cytokine and Th2 chemokine and may be a useful anti-allergic agent.